Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TargeGen has said preliminary data research from a phase I trial suggests that its eye drop was well tolerated in the treatment of macular degeneration and other debilitating diseases of the eye.
Subscribe to our email newsletter
The eye drug TG100801, applied daily in eye drop form, is designed to suppress disease related edema, angiogenesis and inflammation simultaneously. Currently approved therapies for macular degeneration require repeated injection into the eye.
Preliminary results from this phase I study suggest that TG100801 is well tolerated in humans at the low and high doses tested when applied topically twice daily for 14 days.
Final study results are expected by the end of April 2007. TargeGen currently plans to initiate phase II clinical trials in wet age-related macular degeneration patients in mid-2007.
“The successful completion of this 'first in human' safety study with TG100801 represents a meaningful milestone for TargeGen and sets the stage for the near term initiation of human efficacy trials,” stated Peter Ulrich, president, CEO and co-founder of TargeGen.